Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12-month, double-blind, randomized clinical trial

Clinical Therapeutics

Volumn 27, Issue 9, 2005, Pages 1383-1391

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Gaddi, Antonio V ^b   Ciccarelli, Leonardina ^a   Piccinni, Mario N ^a   Salvadeo, Sibilla ^a   Pricolo, Fabio ^a   Fogari, Elena ^a   Ghelfi, Morena ^a   Ferrari, Ilaria ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diabetes mellitus; Glimepiride plus metformin combination; Hypertension; Metabolic syndrome; Rosiglitazone; Sulfonylurea; Thiazolidinediones

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 27744539460     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.09.003     Document Type: Article

References (33)

1. Beckman JA, Creager MA, and Libby P Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. American Diabetes Association Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Clinical practice recommendations 2002 Diabetes Care 25 Suppl 1 2002 S1 S147
3. Vivian EM, and Rubinstein GB Pharmacologic management of diabetic nephropathy Clin Ther 24 2002 1741 1756
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
5. Derosa G, Cicero AF, Ciccarelli L, and Fogari R A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus Clin Ther 25 2003 2006 2021
6. Charpentier G, Fleury F, and Kabir M Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet Med. 18 2001 828 834
7. Riddle M Combining sulfonylureas and other oral agents Am J Med 108 Suppl 6a 2000 15S 22S
8. [WMA Web site] World Medical Association Declaration of Helsinki Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects Accessed June 1, 2005 1989 WMA Ferney-Voltaire, France Accessed June 1, 2005 Accessed June 1, 2005
9. (Suppl) American Diabetes Association Screening for diabetes (Position Statement) Diabetes Care 24 2001 S21 S24
10. World Health Organization (WHO) Obesity: Preventing and Managing the Global Epidemic Report of WHO Consultation on Obesity 1997 WHO Geneva, Switzerland
11. World Health Organization-International Society of Hypertension (WHO-ISH) Guidelines Subcommittee. 1999 WHO-ISH Guidelines for the Management of Hypertension J Hypertens 17 1999 151 183
12. (Suppl) American Diabetes Association Nutrition recommendations and principles for people with diabetes mellitus (Position Statement) Diabetes Care 24 2001 S44 S47
13. Bunn HF, Gabbay HK, and Gallop PM The glycosylation of haemoglobin: Relevance to diabetes mellitus Science 200 1978 21 27
14. European Diabetes Policy Group 1999 A desktop guide to type 2 diabetes mellitus Diabet Med 16 1999 716 730
15. Heding LG Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
16. Matthews DR, Hosker JP, and Rudenski AS Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
17. Winer BJ Statistical Principles in Experimental Design 2nd ed 1971 McGraw-Hill New York, NY
18. Pratt DS, and Kaplan MM Evaluation of abnormal liver-enzyme results in asymptomatic patients N Engl J Med 342 2000 1266 1271
19. (Suppl) Vague P Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 29 2003 6S5 6S7
20. Johnson JA, Majumdar SR, Simpson SH, and Toth EL Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 25 2002 2244 2248
21. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1557] Lancet 352 1998 854 865
22. for the Diabetes Prevention Program Research Group Knowler WC, Barrett-Connor E, and Fowler SE Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
23. McCall AL Clinical review of glimepiride Expert Opin Pharmacother 2 2001 699 713
24. Langtry HD, and Balfour JA Glimepiride. A review of its use in the management of type 2 diabetes mellitus Drugs 55 1998 563 584
25. Stumvoll M Thiazolidinediones - some recent developments Expert Opin Investig Drugs 12 2003 1179 1187
26. Bajaj M, Suraamornkul S, and Pratipanawatr T Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364 1370
27. Abbink EJ, Pickkers P, and Jansen van Rosendaal A Vascular effects of glibenclamide vs. glimepiride and metformin in type 2 diabetic patients Diabet Med 19 2002 136 143
28. Jones TA, Sautter M, Van Gaal LF, and Jones NP Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes Diabetes Obes Metab 5 2003 163 170
29. Shargorodsky M, Wainstein J, and Gavish D Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus [published correction appears in Am J Hypertens. 2003;16:894] Am J Hypertens 16 2003 617 622
30. Derosa G, Mugellini A, and Ciccarelli L Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors Clin Ther 25 2003 472 484
31. Derosa G, Cicero AF, and Gaddi A Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 26 2004 744 754
32. Virtanen KA, Hallsten K, and Parkkola R Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects Diabetes 52 2003 283 290
33. Diamant M, and Heine RJ Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence Drugs 63 2003 1373 1405